Donald P Bottaro

12PUBLICATIONS
50CO-AUTHORS
Gene and molecular therapyCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersChemotherapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|May 12, 2026
Multiplex immunofluorescence microscopy assays for pharmacodynamic assessment of MET tyrosine kinase activation in the plasma membrane and nucleus.

|Jul 02, 2024
Final Results From a Phase I Trial and Expansion Cohorts of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced/Metastatic Genitourinary Tumors.

Andrea B Apolo, Daniel M Girardi, Scot A Niglio

|Jan 21, 2023
Rilotumumab Resistance Acquired by Intracrine Hepatocyte Growth Factor Signaling.

Fabiola Cecchi, Karen Rex, Joanna Schmidt

|Jan 15, 2022
Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy.

Daniel M Girardi, Scot A Niglio, Amir Mortazavi

|Oct 30, 2021
Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas.

Geraldine O'Sullivan Coyne, Shivaani Kummar, James Hu

|Jul 22, 2021
Autocrine signaling by receptor tyrosine kinases in urothelial carcinoma of the bladder.

Young H Lee, Molly M Lee, Dinuka M De Silva

Pageof 2

Frequent Collaborators

4 joint publications

Amir Mortazavi

3 joint publications

Seth M Steinberg

3 joint publications

Daniel M Girardi

3 joint publications

Elad Sharon